1mmLESS THAN

REACH FOR THE FAR CORNERS

OF THE UTERUSApproach challenging

resections with confidence

The MyoSure REACH device: the solution you have been looking for to resect hard-to-reach pathology.

MyoSure.com/REACH

Designed to maximize access for removal of fibroids up to 3 cm

Evolution of the trusted MyoSure® device design

Designed to access hard-to-reach areas, including the upper third

of the uterine cavity

The challenge of hard-to-reach intrauterine pathology

When planning to resect a pathology in a hard-to-reach area, including the upper third of the uterine cavity, do you:

ANTICIPATE PROCEDURAL DIFFICULTY?

EXPECT A LONGER-THAN-AVERAGE PROCEDURE?

ANATOMICALLY CHALLENGING PATHOLOGY

POTENTIAL CASE STUDYAbnormal uterine bleeding in a 45-year-old woman • Chief complaint: heavy menstrual

bleeding x 6 months

• Nulliparity, hypertension, obesity

• Saline-infused sonohysterography: polypoid lesion identified, originating from the fundus, measuring 1.5 cm in diameter

Approaches to resecting hard-to-reach pathology

APPROACH RATIONALE LIMITATIONS

Grasping forceps • Inexpensive

• Easy to use

• Reprocessable

• Requires manual evacuation of remaining tissue pathology

• Nonvisualized insertion of instrument

• Struggle to completely remove pathology1

Resection with electrical energy (eg, bipolar loop resection)

• Done under direct visualization

• Tested and proven

• Risk of thermal injury to adjacent, healthy uterine tissue2

Switching instrumentation for resection during procedure when necessary

• Adapting the procedure to the challenges that arise

• Time-consuming

• Expensive

REACH for the far corners of the uterus

APPROACH CHALLENGING RESECTIONS WITH CONFIDENCE

• Designed to maximize access for removal of fibroids up to 3 cm

• Evolution of the trusted MyoSure device design with all of the capabilities of the original

• Designed to access hard-to-reach areas, including the upper third of the uterine cavity

Introducing the MyoSure® REACH device

cutting window is less than

1 mm from the distal tip

<1mm

Licensed material is being used for illustrative purposes only. Any person depicted in the licensed material is a model.

SS-00370-001 Rev. 001 ©2016 Hologic, Inc. Hologic, MyoSure, The Science of Sure, and associated logos are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

REFERENCES: 1. Di Spiezio Sardo A, Calagna G, Guida M, Perino A, Nappi C. Hysteroscopy and treatment of uterine polyps. Best Pract Res Clin Obstet Gynaecol. 2015;29:908-919. 2. Alkatout I, Schollmeyer T, Hawaldar NA, Sharma N, Mettler L. Principles and safety measures of electrosurgery in laparoscopy. JSLS. 2012;16:130-139. 3. Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 2001;80(12):1131-1136. 4. Salim S, Nesbitt-Hawes E, Campbell N, Abbott J. Diagnosis and management of endometrial polyps: a critical review of the literature. J Minim Invasive Gynecol. 2011;18(5):569-581.

Contact a sales representative or visit MyoSure.com/REACH to learn more.

ORDERING INFORMATION

DESCRIPTION ORDER NUMBER

MyoSure REACH device — 3 devices per box 10-403FC

MyoSure LITE device — 3 devices per box 30-403LITE

MyoSure device — 3 devices per box 10-403

MyoSure XL device — 3 devices per box 50-503XL

MyoSure control unit with foot pedal 10-550

What effect could the utility of the MyoSure REACH device have on your patients?

COMPLETE RESECTION OF BENIGN LESIONS MAY DECREASE LIKELIHOOD

OF SYMPTOM RECURRENCE3

UP TO 12.9% OF POLYPS MAY BE MALIGNANT4

IMPROVED ACCESS TO HARD-TO-REACH PATHOLOGY

HELPS TO IMPROVE OPERATIVE EFFICIENCY

THE MYOSURE® TISSUE REMOVAL SYSTEM SIMPLIFIES THE STANDARD OF CARE

IMPORTANT SAFETY INFORMATIONThe MyoSure® tissue removal system is intended for hysteroscopic intrauterine procedures by trained gynecologists to resect and remove tissue including submucous myomas, endometrial polyps, and retained products of conception. It is not appropriate for patients who are or may be pregnant, or are exhibiting pelvic infection, cervical malignancies, or previously diagnosed endometrial cancer..